THE PROGNOSTIC-SIGNIFICANCE OF DNA FLOW-CYTOMETRY IN BREAST-CANCER - RESULTS FROM 881 PATIENTS TREATED IN A SINGLE-CENTER

被引:51
作者
CAMPLEJOHN, RS [1 ]
ASH, CM [1 ]
GILLETT, CE [1 ]
RAIKUNDALIA, B [1 ]
BARNES, DM [1 ]
GREGORY, WM [1 ]
RICHARDS, MA [1 ]
MILLIS, RR [1 ]
机构
[1] GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND
关键词
FLOW CYTOMETRY; BREAST CANCER; S-PHASE FRACTION; PLOIDY; PROGNOSIS;
D O I
10.1038/bjc.1995.29
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this single-centre study of 881 patients, S-phase fraction (SPF) was shown to be a significant prognostic marker in terms of overall survival (OS), relapse-free survival (RFS) and survival after relapse (SAR). Further, SPF had independent prognostic significance when considering a range of other clinicopathological variables, namely tumour grade and stage, nodal status, patient age, tumour size, menstrual status and treatment details. For OS and RFS, SPF was the second strongest predictor of the clinical course of the disease after nodal status, and for SAR it was the strongest prognostic marker. SPF correlated positively with histological grade but was the stronger predictor of survival. The distribution of SPF values was markedly different for the two ploidy classes of tumour, with DNA aneuploid tumours having a significantly higher average SPF. However, SPF retained its independent prognostic ability when DNA diploid and aneuploid tumours were analysed separately, DNA ploidy itself also proved to be an independent prognostic marker but the survival difference between the two ploidy classes was much less than that seen for different levels of SPF. Tumours with several DNA aneuploid populations (multiploid tumours) tended to have a worse prognosis than other aneuploid tumours but this trend did not reach statistical significance. In this and other studies from this centre, SPF has proved to be a robust predictor of clinical outcome in carcinoma of the breast.
引用
收藏
页码:140 / 145
页数:6
相关论文
共 34 条
  • [1] ANALYSIS OF PCP-DATA TO DETERMINE FRACTION OF CELLS IN VARIOUS PHASES OF CELL-CYCLE
    BAISCH, H
    GOHDE, W
    LINDEN, WA
    [J]. RADIATION AND ENVIRONMENTAL BIOPHYSICS, 1975, 12 (01) : 31 - 39
  • [2] OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE
    BARNES, DM
    BARTKOVA, J
    CAMPLEJOHN, RS
    GULLICK, WJ
    SMITH, PJ
    MILLIS, RR
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 644 - 648
  • [3] KI67 IMMUNOSTAINING IN PRIMARY BREAST-CANCER - PATHOLOGICAL AND CLINICAL ASSOCIATIONS
    BOUZUBAR, N
    WALKER, KJ
    GRIFFITHS, K
    ELLIS, IO
    ELSTON, CW
    ROBERTSON, JFR
    BLAMEY, RW
    NICHOLSON, RI
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (06) : 943 - 947
  • [4] MARKERS OF PROGNOSIS IN BREAST-CANCER - THE RELATIONSHIP BETWEEN BINDING OF THE LECTIN HPA AND HISTOLOGICAL GRADE, SPF, AND PLOIDY
    BROOKS, SA
    LEATHEM, AJC
    CAMPLEJOHN, RS
    GREGORY, W
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1993, 25 (03) : 247 - 256
  • [5] A ROLE FOR PROLIFERATIVE MEASUREMENTS IN CLINICAL ONCOLOGY
    CAMPLEJOHN, R
    [J]. ANNALS OF ONCOLOGY, 1993, 4 (03) : 184 - 186
  • [6] MEASUREMENT OF S-PHASE FRACTIONS IN LYMPHOID-TISSUE COMPARING FRESH VERSUS PARAFFIN-EMBEDDED TISSUE AND 4',6'-DIAMIDINO-2 PHENYLINDOLE DIHYDROCHLORIDE VERSUS PROPIDIUM IODIDE STAINING
    CAMPLEJOHN, RS
    MACARTNEY, JC
    MORRIS, RW
    [J]. CYTOMETRY, 1989, 10 (04): : 410 - 416
  • [7] CAMPLEJOHN RS, 1992, CELL PROLIFERATION C, P95
  • [8] CAMPLEJOHN RS, 1992, DIAGNOSTIC MOL PATHO, P238
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] DNA FLOW-CYTOMETRY, NUCLEAR MORPHOMETRY, MITOTIC INDEXES AND STEROID-RECEPTORS AS INDEPENDENT PROGNOSTIC FACTORS IN FEMALE BREAST-CANCER
    ESKELINEN, M
    LIPPONEN, P
    PAPINAHO, S
    AALTOMAA, S
    KOSMA, VM
    KLEMI, P
    SYRJANEN, K
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (04) : 555 - 561